ERBB2 and neoplasm: In trials providing data, the median participant age was 53 years (IQR 46–60), and of 18 103 women, 9731 (53%) had cancers with lymph node involvement, 12 244 (67%) had ER-positive tumours, and 2577 (14%) had HER2-positive tumours.